UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT00175825
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
Phase 3
Withdrawn
- Conditions
- Epilepsy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00175864
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 857
- Registration Number
- NCT00175877
- Locations
- 🇺🇸
152, Huntsville, Alabama, United States
🇺🇸148, San Diego, California, United States
🇺🇸153, Danbury, Connecticut, United States
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 853
- Registration Number
- NCT00175916
- Locations
- 🇺🇸
935, San Francisco, California, United States
🇺🇸933, Gainesville, Florida, United States
🇺🇸931, Charlottesville, Virginia, United States
A Study of Brivaracetam in Subjects With Partial Onset Seizures
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 157
- Registration Number
- NCT00175929
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 567
- Registration Number
- NCT00160641
- Locations
- 🇺🇸
172, Palm Desert, California, United States
🇺🇸185, Pasadena, California, United States
🇺🇸170, Santa Maria, California, United States
Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures
Phase 3
Completed
- Conditions
- Generalized Convulsive Epilepsy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 154
- Registration Number
- NCT00160550
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 590
- Registration Number
- NCT00160602
Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
Phase 3
Completed
- Conditions
- Epilepsy, Partial
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT00160628
A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
Phase 2
Completed
- Conditions
- Neuralgia, Postherpetic
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT00160511